â– LECTURE OVERVIEW: Diabetic Retinopathy is a microvascular complication of chronic diabetes, classified into Non-Proliferative (NPDR) and Proliferative (PDR) phases.
â– PATHOPHYSIOLOGIC MECHANISMS:
1. Sorbitol Depletion: Chronic hyperglycemia drives intracellular aldose reductase to convert glucose to sorbitol. Sorbitol accumulation causes osmotic stress, selectively destroying pericytes.
2. Microaneurysms: Loss of supporting pericytes weakens capillary walls, leading to microaneurysms and leakage.
3. Systemic Retinal Ischemia: Progressive capillary closures cause retinal ischemia.
4. VEGF Surge: Ischemic retinocytes synthesize and secrete high-yield levels of Vascular Endothelial Growth Factor (VEGF).
5. Neovascularization: Excess VEGF drives neovascularization—the growth of fragile, abnormal new blood vessels over the optic disc and retina.
6. Hemorrhage and Traction: These fragile vessels are prone to rupture, leading to vitreous hemorrhage and subsequent fibrous scarring that can cause tractional retinal detachment.
â– TOXICOLOGICAL OVERDOSAGE PROTOCOL:
Toxic absorption or cumulative exposure results in receptor saturation, chemical cell damage, or severe secondary target-organ failure. Immediate toxicological profiles dictate serum or urine screens.
â– SUBCLINICAL PHENOTYPE DYNAMICS:
Early physiological shifts typically occur without overt symptom presentation, necessitating highly sensitive laboratory screening to detect disease onset.
[HY-BOARD-1219]
🌟 Dynamic Clinical Key:
To prevent blindness, patients with proliferative diabetic retinopathy are treated with intravitreal anti-VEGF monoclonal antibodies (e.g., Bevacizumab, Ranibizumab) and pan-retinal photocoagulation (PRP) to ablate outer ischemic areas and reduce VEGF release. Administer physiological antidotes and active elimination therapies (activated charcoal or hemodialysis) without delay. Monitor high-sensitivity panels regularly in at-risk cohorts to enable timely preventative actions.